M1 Kliniken AG

  • WKN: A0STSQ
  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 15.12.2020 | 15:10

M1 Kliniken AG disposes subsidiary 'M1 Aesthetics GmbH' to HAEMATO AG - Transfer of the holding of the company within the scope of a capital increase in kind of HAEMATO AG AG:

DGAP-News: M1 Kliniken AG / Key word(s): Investment/Disposal
15.12.2020 / 15:10
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG disposes subsidiary "M1 Aesthetics GmbH" to HAEMATO AG - Transfer of the holding of the company within the scope of a capital increase in kind of HAEMATO AG

Berlin, 15.12.2020 - M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind. For this purpose, the Management Board of HAEMATO AG decided today with the approval of the Supervisory Board to increase the company's share capital by EUR 2,467,201 to EUR 4,753,916 by issuing 2,467,201 new shares of HAEMATO AG through a capital increase against contribution in kind under exclusion of the subscription right of the shareholders by using the existing authorised capital. The new shares will be subscribed and taken over exclusively by M1 Kliniken AG. The transaction will be implemented with effect from 1.01.2021. After completion of the transaction, M1 Kliniken AG will hold a total of 75.8% of the share capital of HAEMATO AG.

With this transaction, M1 Kliniken AG is pursuing its strategy to focus the company on the beauty treatment business, which began in mid-2020, while the trading and product business will be bundled in the subsidiary HAEMATO AG. In addition the combination of the product and trading activities of M1 Aesthetics under the umbrella of HAEMATO AG, it is the long-term strategy of the M1 Kliniken Group to increase the vertical integration of its own activities. To this end, it is intended to establish a selection of high-quality treatment products (hyaluronic acid and botulinum toxin) as a "M1 private label" in the medium term and thereby strengthen the earning power, especially in the entry-level price segment.

Dr. Walter von Horstig, Member of the Board of Directors of M1 Kliniken AG, comments on the transaction as follows: "The implementation of our strategy "Quality does not have to be expensive" repeatedly calls for the development of value creation potential. Our long-term private label strategy will be an important element in this respect in the future. Favourable prices mean a larger market with simultaneously rising margins from the various stages of the value chain. HAEMATO AG's established development platform is an ideal starting point for this and will help us to implement the strategy quickly and securely".

M1 Aesthetics GmbH was valued on the basis of an IDW-S1 expert opinion with an enterprise value of a good € 58 million. The new HAEMATO shares were issued at a reference price of €23.55 per share, which corresponds to the volume-weighted average price of HAEMATO AG in the Xetra trading system in the period from 27.11.2020 to 9.12.2020.

In 2019 M1 Aesthetics GmbH reported sales of about 51 million Euro and an EBIT of almost 7 million Euro. For 2020, M1 Aesthetics GmbH is expecting sales of a good EUR 30 million and an EBIT of approximately EUR 4 million - also due to corona effects, among other things. A further increase in earnings is expected in the coming years.

About M1 Kliniken AG
M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik für plastische und ästhetische Chirurgie in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England and Australia.




Contact:
M1 Kliniken AG
Dr. Walter von Horstig, Management Board
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de


15.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021